查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980739

全球心絞痛治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Angina Pectoris Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，心絞痛治療市場規模將從 2025 年的 29.7 億美元成長至 43.7 億美元，2026 年至 2034 年的複合年成長率為 4.41%。

由於全球心血管疾病發生率不斷上升，全球心絞痛治療市場正穩定擴張。心絞痛的特徵是由於心臟供血不足引起的胸痛，在老齡化社會以及存在肥胖、吸煙和高血壓等文明病因素的人群中仍然十分常見。需要長期心血管管理的患者數量不斷成長，顯著推動了對有效藥物療法的需求，這些療法有助於緩解症狀並提高患者的生活品質。

推動市場成長的因素包括藥物研發的進步、新藥製劑的開發以及人們對心臟病早期診斷和治療意識提升。各國政府和醫療機構也正在實施心血管健康改善計劃，這進一步刺激了對心絞痛藥物的需求。此外，學名藥的廣泛普及使已開發國家和開發中國家的更多患者都能獲得治療選擇，從而提高了藥物的可近性和可負擔性。

全球心絞痛治療市場預計將保持強勁成長，這主要得益於持續研發帶來的安全性和有效性不斷提升的創新治療方法的不斷湧現。製藥公司正大力投資藥物研發和臨床試驗，以滿足心血管疾病治療領域尚未滿足的需求。此外，個人化醫療的日益普及以及新興市場醫療基礎設施的改善，預計將為市場擴張創造新的機會。鑑於心血管疾病管理仍然是全球關注的重點，心絞痛治療市場預計將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球心絞痛治療市場：依類型分類

  • 市場分析、洞察與預測
  • 穩定性心絞痛
  • 不穩定型心絞痛
  • 微血管性心絞痛
  • 變異型心絞痛

第5章 全球心絞痛治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • BETA阻斷劑
  • 硝酸鹽
  • 抗血小板藥物
  • 鈣離子通道阻斷劑
  • 抗凝血劑
  • ACE抑制劑
  • 其他藥物類別

第6章：全球心絞痛治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物
  • 局部的

第7章 全球心絞痛治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球心絞痛治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AdvaCare Pharma
    • Amgen
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim International
    • Eli Lilly And Company
    • Gilead Sciences
    • GlaxoSmithKline
    • Merck
    • Novartis
    • Otsuka Pharmaceutical
    • Pfizer
    • Sanofi
簡介目錄
Product Code: VMR112115166

The Angina Pectoris Drugs Market size is expected to reach USD 4.37 Billion in 2034 from USD 2.97 Billion (2025) growing at a CAGR of 4.41% during 2026-2034.

The Global Angina Pectoris Drugs Market is expanding steadily due to the increasing incidence of cardiovascular diseases across the world. Angina pectoris, characterized by chest pain caused by reduced blood flow to the heart, remains a common condition among aging populations and individuals with lifestyle-related risk factors such as obesity, smoking, and hypertension. The growing patient pool requiring long-term cardiovascular management is significantly boosting the demand for effective drug therapies that help alleviate symptoms and improve patient quality of life.

Several factors are driving market growth, including advancements in pharmaceutical research, the development of novel drug formulations, and increased awareness regarding early diagnosis and treatment of heart diseases. Governments and healthcare organizations are also implementing programs aimed at improving cardiovascular health, which further supports the demand for angina medications. In addition, the expanding availability of generic drugs has improved accessibility and affordability, making treatment options available to a broader patient base across both developed and developing regions.

Future prospects for the Global Angina Pectoris Drugs Market remain strong as ongoing research continues to introduce innovative therapies with improved safety and efficacy profiles. Pharmaceutical companies are investing heavily in drug development and clinical trials to address unmet medical needs in cardiovascular care. Furthermore, the growing adoption of personalized medicine and improved healthcare infrastructure in emerging economies are expected to create new opportunities for market expansion. As cardiovascular disease management remains a global priority, the angina pectoris drugs market is anticipated to witness sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Stable Angina
  • Unstable Angina
  • Microvascular Angina
  • Prinzmetal Angina

By Drug Class

  • Beta Blockers
  • Nitrates
  • Anti-Platelets
  • Calcium Channel Blockers
  • Anticoagulants
  • Ace Inhibitors
  • Other Drug Classes

By Route Of Administration

  • Oral
  • Injectable
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • AdvaCare Pharma, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim International, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Sanofi
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Stable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Unstable Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Microvascular Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Prinzmetal Angina Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Nitrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Anti-Platelets Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Calcium Channel Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Ace Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANGINA PECTORIS DRUGS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Type
    • 8.2.2 By Drug Class
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Type
    • 8.3.2 By Drug Class
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Type
    • 8.4.2 By Drug Class
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Type
    • 8.5.2 By Drug Class
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Type
    • 8.6.2 By Drug Class
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANGINA PECTORIS DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AdvaCare Pharma
    • 10.2.2 Amgen
    • 10.2.3 AstraZeneca
    • 10.2.4 Bayer
    • 10.2.5 Boehringer Ingelheim International
    • 10.2.6 Eli Lilly And Company
    • 10.2.7 Gilead Sciences
    • 10.2.8 GlaxoSmithKline
    • 10.2.9 Merck
    • 10.2.10 Novartis
    • 10.2.11 Otsuka Pharmaceutical
    • 10.2.12 Pfizer
    • 10.2.13 Sanofi